Overview

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate 12 weeks progression-free survival (PFS) rate of Palbociclib plus Letrozole in ER/PR positive endometrioid or high-grade serous ovarian cancer who have disease progression on second-line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Latin American Cooperative Oncology Group

Collaborator:

Pfizer

Treatments:

Letrozole
Palbociclib